Brown Brothers Harriman & Co’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.7M | Buy |
8,968
+699
| +8% | +$131K | 0.01% | 391 |
|
|
2026
Q1 | $1.63M | Buy |
8,269
+2,289
| +38% | +$441K | 0.01% | 346 |
|
|
2025
Q4 | $1.1M | Buy |
5,980
+1,376
| +30% | +$241K | 0.01% | 357 |
|
|
2025
Q3 | $706K | Buy |
4,604
+18
| +0.4% | +$2.72K | ﹤0.01% | 410 |
|
|
2025
Q2 | $641K | Buy |
4,586
+1,639
| +56% | +$230K | ﹤0.01% | 412 |
|
|
2025
Q1 | $433K | Sell |
2,947
-424
| -13% | -$61.3K | ﹤0.01% | 419 |
|
|
2024
Q4 | $442K | Buy |
3,371
+118
| +4% | +$16.5K | ﹤0.01% | 428 |
|
|
2024
Q3 | $507K | Buy |
3,253
+222
| +7% | +$35.8K | ﹤0.01% | 400 |
|
|
2024
Q2 | $473K | Buy |
3,031
+108
| +4% | +$16.3K | ﹤0.01% | 387 |
|
|
2024
Q1 | $396K | Sell |
2,923
-20
| -0.7% | -$2.65K | ﹤0.01% | 396 |
|
|
2023
Q4 | $396K | Sell |
2,943
-331
| -10% | -$43K | ﹤0.01% | 384 |
|
|
2023
Q3 | $443K | Buy |
3,274
+257
| +9% | +$35.1K | ﹤0.01% | 359 |
|
|
2023
Q2 | $432K | Sell |
3,017
-270
| -8% | -$39.7K | ﹤0.01% | 346 |
|
|
2023
Q1 | $456K | Buy |
3,287
+378
| +13% | +$50.9K | ﹤0.01% | 352 |
|
|
2022
Q4 | $394K | Sell |
2,909
-271
| -9% | -$34K | ﹤0.01% | 350 |
|
|
2022
Q3 | $349K | Buy |
3,180
+583
| +22% | +$74K | ﹤0.01% | 363 |
|
|
2022
Q2 | $343K | Buy |
2,597
+309
| +14% | +$40.5K | ﹤0.01% | 371 |
|
|
2022
Q1 | $304K | Buy |
2,288
+1,979
| +640% | +$237K | ﹤0.01% | 422 |
|
|
2021
Q4 | $36K | Hold |
309
| – | – | ﹤0.01% | 754 |
|
|
2021
Q3 | $37K | Buy |
309
+218
| +240% | +$25.4K | ﹤0.01% | 725 |
|
|
2021
Q2 | $11K | Hold |
91
| – | – | ﹤0.01% | 880 |
|
|
2021
Q1 | $9K | Sell |
91
-100
| -52% | -$10.1K | ﹤0.01% | 875 |
|
|
2020
Q4 | $19K | Buy |
191
+128
| +203% | +$13.6K | ﹤0.01% | 785 |
|
|
2020
Q3 | $7K | Hold |
63
| – | – | ﹤0.01% | 789 |
|
|
2020
Q2 | $7K | Sell |
63
-32
| -34% | -$3.31K | ﹤0.01% | 778 |
|
|
2020
Q1 | $8K | Buy |
95
+32
| +51% | +$3.01K | ﹤0.01% | 717 |
|
|
2019
Q4 | $6K | Sell |
63
-593
| -90% | -$55.8K | ﹤0.01% | 955 |
|
|
2019
Q3 | $58K | Hold |
656
| – | – | ﹤0.01% | 619 |
|
|
2019
Q2 | $54K | Buy |
656
+593
| +941% | +$46.5K | ﹤0.01% | 575 |
|
|
2019
Q1 | $5K | Sell |
63
-56
| -47% | -$4.41K | ﹤0.01% | 896 |
|
|
2018
Q4 | $9K | Hold |
119
| – | – | ﹤0.01% | 696 |
|
|
2018
Q3 | $9K | Buy |
+119
| New | +$9K | ﹤0.01% | 685 |
|
|
2017
Q2 | – | Sell |
-176
| Closed | -$11K | – | 750 |
|
|
2017
Q1 | $11K | Buy |
+176
| New | +$10.2K | ﹤0.01% | 644 |
|
|
2015
Q4 | – | Sell |
-654
| Closed | -$42K | – | 742 |
|
|
2015
Q3 | $42K | Buy |
+654
| New | +$43K | ﹤0.01% | 512 |
|
|
2015
Q1 | – | Sell |
-1,850
| Closed | -$130K | – | 763 |
|
|
2014
Q4 | $130K | Hold |
1,850
| – | – | ﹤0.01% | 408 |
|
|
2014
Q3 | $132K | Sell |
1,850
-50
| -3% | -$3.66K | ﹤0.01% | 403 |
|
|
2014
Q2 | $141K | Buy |
+1,900
| New | +$137K | ﹤0.01% | 396 |
|
|
2013
Q3 | – | Sell |
-17
| Closed | -$1K | – | 704 |
|
|
2013
Q2 | $1K | Buy |
+17
| New | +$866 | ﹤0.01% | 706 |
|
Other funds holding AZN
EP
IA
Brown Brothers Harriman & Co's AZN Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its AstraZeneca (AZN) stake by 8.5% in Q2 2026, buying an estimated $131K and bringing the position to 8,968 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #391.
Brown Brothers Harriman & Co first reported a position in AZN in Q2 2013 and has held it in 38 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Brown Brothers Harriman & Co held 8,968 shares of AstraZeneca worth $1.7M as of Q2 2026.
- Brown Brothers Harriman & Co bought 699 AstraZeneca shares in Q2 2026, an estimated $131K.
- AstraZeneca made up 0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #391 holding.
- Brown Brothers Harriman & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 38 quarters since.
- 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.